Literature DB >> 23521523

Comparison of testing approaches for Clostridium difficile infection at a large community hospital.

J D Grein1, M Ochner, H Hoang, A Jin, M A Morgan, A R Murthy.   

Abstract

Multiple diagnostic approaches are available for Clostridium difficile infection (CDI); current guidelines support two-step testing (2ST) as the preferred approach. We retrospectively evaluated the impact of switching from toxin enzyme immunoassay (EIA) to 2ST, and then to polymerase chain reaction (PCR), on CDI rates, test utilization and CDI treatment at a 900-bed tertiary care community teaching hospital. All inpatients tested for CDI between December 2008 and February 2011 were included. A positive toxin EIA or PCR was diagnostic of CDI; 2ST was performed using glutamate dehydrogenase EIA, followed by PCR if positive. Repeat tests within 8 weeks on the same patient were considered part of the same testing episode. Data were collected electronically and studied in aggregate from 9725 unique inpatients tested for CDI, representing 20 836 individual tests. PCR detected 41% more patients with CDI than toxin EIA (p <0.0001), and 15% more than 2ST (p 0.02), corresponding to higher hospital-onset and community-onset CDI rates. The number of CDI tests performed per patient decreased by 48% with PCR (p <0.0001) compared with toxin EIA. For patients with CDI, time to the first positive test result was shortest with PCR. For patients without CDI, a negative PCR, but not 2ST, was associated with 22% fewer CDI treatment days, compared with toxin EIA (p <0.0001). Compared with both toxin EIA and 2ST, PCR detected more CDI patients faster and with less frequent testing, and negative PCR results were associated with less empirical CDI treatment.
© 2013 The Authors Clinical Microbiology and Infection © 2013 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Clostridium difficile; PCR; infection; nosocomial; testing algorithm; two-step testing

Mesh:

Substances:

Year:  2013        PMID: 23521523     DOI: 10.1111/1469-0691.12198

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

1.  Cost and Impact on Patient Length of Stay of Rapid Molecular Testing for Clostridium difficile.

Authors:  Bernadette Sewell; Eugene Rees; Ian Thomas; Chin Lye Ch'ng; Mike Isaac; Nidhika Berry
Journal:  Infect Dis Ther       Date:  2014-09-03

2.  Clinical and economic impact of the introduction of a nucleic acid amplification assay for Clostridium difficile.

Authors:  Margaret M Guinta; Kristen Bunnell; Amanda Harrington; Susan Bleasdale; Larry Danziger; Eric Wenzler
Journal:  Ann Clin Microbiol Antimicrob       Date:  2017-12-04       Impact factor: 3.944

3.  A mathematical model of Clostridium difficile transmission in medical wards and a cost-effectiveness analysis comparing different strategies for laboratory diagnosis and patient isolation.

Authors:  Vered Schechner; Yehuda Carmeli; Moshe Leshno
Journal:  PLoS One       Date:  2017-02-10       Impact factor: 3.240

4.  Impact of the introduction of a nucleic acid amplification test for Clostridium difficile diagnosis on stool rejection policies.

Authors:  J Goret; J Blanchi; P Floch; O Peuchant; D Chrisment; R Sanchez; H Biessy; R Lemarié; D Leyssene; B Loutfi; S Mimouni; T Flao; C Bébéar; F Mégraud
Journal:  Gut Pathog       Date:  2018-05-30       Impact factor: 4.181

Review 5.  Direct Measurement of Performance: A New Era in Antimicrobial Stewardship.

Authors:  Majdi N Al-Hasan; Hana Rac Winders; P Brandon Bookstaver; Julie Ann Justo
Journal:  Antibiotics (Basel)       Date:  2019-08-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.